Riskpilot← Back to searchSign inGet full accessMartin Dahl Medtech AB
ABActiveOrg 5568655426Torget 47General medical practice activities · NACE 8621Est. 20110 employees
Revenue 2025
SEK 882K
-1% vs 2024
EBITDA margin
44.2%
+796% vs 2024
Equity ratio
48.3%
Financial strength
Net profit 2025
SEK 222K
+13% vs 2024
| Revenue | SEK 882K | -1% |
| EBITDA | SEK 389K | +796% |
| Net profit | SEK 222K | +13% |
| Total assets | SEK 903K | -17% |
| Equity | SEK 436K | +5% |
| Employees | 0 | — |
Legal name
Martin Dahl Medtech AB
Org number
5568655426
Legal form
Aktiebolag
NACE code
8621 · General medical practice activities
Founded
24 september 2011
Share capital
SEK 50 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Bolaget skall bedriva: 1. Konsultationstjänster inom området medicnteknik 2. Försäljning av medicintekniska produkter 3. Handel med värdepapper 4. Handel med båtar och båttillbehör Samt idka därmed förenlig verksamhet.
Address
Torget 47
Email
martin.dahl@euromail.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 1 416 | 893 | 882 |
| Staff expenses | — | — | −116 | −777 | −345 |
| EBITDA | −2 | −1 | 1 182 | 43 | 389 |
| Depreciation & amort. | −0 | — | — | −7 | −7 |
| EBIT | −2 | −1 | 1 182 | 36 | 382 |
| Net financials | — | — | 0 | 14 | −2 |
| Profit before tax | −2 | −1 | 907 | 250 | 282 |
| Tax | −0 | — | −170 | −54 | −61 |
| Net profit | −2 | −1 | 737 | 196 | 222 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 1 | 1 | 1 262 | 1 088 | 903 |
| Equity | −18 | −19 | 718 | 415 | 436 |
| Long-term debt | 0 | — | — | — | — |
| Short-term debt | 19 | 20 | 268 | 598 | 293 |
| Total debt | 19 | 20 | 268 | 598 | 293 |
EBITDA margin
44.2%
This company
15.8%
Market median
+180% vs market
20212025
Equity ratio
48.3%
This company
38.2%
Market median
+26% vs market
20212025
Return on equity
50.8%
This company
18.4%
Market median
+176% vs market
20212025
Net profit margin
25.1%
This company
8.1%
Market median
+210% vs market
20212025
Asset turnover
0.98×
This company
1.12×
Market median
+13% vs market
20212025
Debt / equity
1.07×
This company
0.62×
Market median
-73% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
No data on file.
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Deputy Board Member | 2022 | |
| Board of Directors | 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Martin Dahl Medtech AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Maria Elisabeth Dahl | Deputy Board Member | 0 companies |
| Martin Lennart Dahl | Board of Directors | 0 companies |